Improved Joint Mobility Associated with Reduced Inflammation Related to Consumption of Nopal Cactus Fruit Juice: Results from a Placebo-Controlled Trial Using Digital Inclinometry to Objectively Document Mobility of All Major Joints.

OBJECTIVE: To evaluate the effects of daily consumption of Nopal cactus fruit juice (NFJ) on joint mobility in a population experiencing chronic pain but otherwise in good health. STUDY
DESIGN: A double-blind, placebo-controlled study design was used to enroll 40 people after written informed consent, randomized to consume 3 oz/day of NFJ versus placebo. At baseline and 8 weeks, joint range of motion (ROM) was examined by digital inclinometry along the vertical weight-bearing axis of the body from neck to knees and the shoulders. Blood samples were tested for cytokines and C-reactive protein (CRP). Questionnaires addressed wellness, pain, and reliance on pain medications.
RESULTS: After 8 weeks of consuming NFJ, participants showed improved ROM beyond that of participants consuming placebo. Cervical and thoracic/lumbar ROM for the NFJ group was significantly improved when compared to placebo (cervical: P<0.03, thoracic/lumbar: P<0.04). People consuming NFJ relied less on pain medication to complete daily activities (P<0.1) and experienced reduced interference from pain and breathing issues (not significant). Serum levels of Eotaxin, involved in airway inflammation, showed significant differences between placebo and NFJ groups after 8 weeks (P<0.048). Changes in CRP levels showed a larger reduction in the NFJ group (-13%) than in the placebo group (-4%) (not significant). In the subgroup with CRP levels between 1 and 9.9 mg/L at baseline, CRP levels decreased in the NFJ group (-30%) but increased in the placebo group (31%) (P<0.015).
CONCLUSION: Consumption of NFJ for 8 weeks was associated with statistically significant improvements in joint mobility and physical functioning compared to the placebo group, allowing participants in the NFJ group to be more physically active; daily activities were easier, including walking, sitting, and lying. This was associated with reduced use of pain medication, possibly associated with anti-inflammatory properties of NFJ, as suggested by reduced Eotaxin and CRP levels.

Introduction

As we age, physical activity plays a major role in staying healthy. Maintaining a physically active lifestyle has been associated with lower risk of osteoporosis, prevention of loss of muscle mass, improved cardiovascular health, and delayed onset of cognitive decline and dementia.1 Being able to stay active prolongs the time an individual can maintain independent living, and not only does this benefit personal wellness, but also has major economic impacts on personal and societal costs of assisted living and caring for the elderly.2,3

Mobility is a key component in maintaining a physically active lifestyle. It is a recognized factor and subject for clinical trials in programs to improve mobility and delay risk of frailty in the ageing population,4 whether by walking5 or stationary resistance strength exercises.6 In a 14-year longitudinal study of over 4000 non-institutionalized elderly participants, it was shown that physical activity reduced total and cardiovascular death rates.7 In participants in poor health, there is an association between reduced joint mobility and obesity.8 Reduced body weight changes stress on various joints, and has impacts on gait and general mobility.9 At the cellular level, it has been suggested that exercise training increases the mitochondrial bioenergetics, thereby supporting cellular energy production.10 However, painful musculoskeletal ailments limit the ability of people to make necessary lifestyle changes.11

Joint function and mobility are negatively affected by inflammation. Chronic pain in joints and muscles is associated with low-grade inflammation and sets the stage for declining cardiovascular health. Monitoring acute and chronic inflammation often includes testing for C-reactive protein levels as a non-specific marker for inflammation. Elevated blood level of C-reactive protein is an indication of inflammation, either as an indication of chronic inflammatory illness or as a risk marker for cardiovascular disease, and is also associated with increased risk for stroke, diabetes, and neurodegenerative diseases.12 People experiencing long-term chronic inflammatory problems frequently consume over-the-counter or prescription pain medications to be able to complete daily physical activities. Managing pain with pharmaceutical intervention is not ideal and carries risks of side effects, including gastrointestinal discomfort and bleeding13 and kidney damage.14

There is an urgent and global need for effective evidence-based interventions for healthy aging,15 including effective, low-cost nutritional strategies. Research has shown that consuming certain spices such as curcumin helps reduce joint pain.16,17 Fermented fruits, such as papaya, have shown strong antioxidant effects, with anti-inflammatory and anti-ageing effects, including increased telomerase activity and telomere length in an animal model.18 Consuming algae-based extracts rich in the light-harvesting pigment Phycocyanin has been shown to be a safe food-based method to achieve significant pain reduction both when at rest and when physically active.19 Plant-based anti-inflammatory compounds have been studied for their effects on joint mobility, including the anthocyanin-rich juice from Acai berries,20 ergothioneine extracted from mushrooms,21 and polyphenol-rich apple peel powder.22

A unique type of anti-inflammatory compounds are the red plant pigments betalains, which are different from anthocyanins and never found in the same plants.23 A source of betalains is beet root, known to support healthy blood pressure levels,24 via reduction of oxidative stress and inflammation.25 Another source of betalains is the lesser-studied fruit of the Nopal cactus, responsible for the pink and red colors of the fruit. The fruit also contains the fibers and other anti-inflammatory compounds present in the cactus stems, also called cladodes. The Nopal cactus has been used in traditional folk medicine throughout millennia,26 and is currently being researched for metabolic27,28 and anti-inflammatory benefits when added to common foods.29,30

In a previous clinical study, we reported preliminary evidence for anti-inflammatory effects of consuming Nopal fruit juice.31 The placebo-controlled nutritional intervention study reported here was performed to evaluate the potential benefits of consuming the betalain-rich Nopal fruit juice on objective measures of joint mobility and C-reactive protein, as well as questionnaire-based data collection on pain, physical functioning, and daily activities. It was of particular importance to evaluate objective joint mobility across the vertical weight-bearing axis of the body, since the functionality of neck and back plays a major role in the ability to perform daily activities and retain an active lifestyle.

Materials and Methods

Clinical Study Design

Study Design

A double-blinded, randomized, placebo-controlled, parallel-arm clinical study design was used, performed in accordance with the principles stated in the Declaration of Helsinki (trial registration number NCT03619265). The study involved 40 people, enrolled after screening for moderate levels of chronic pain (a minimum score of 4 out of 20, lasting at least 6 months prior to the study) and signing written informed consent. Each study participant was randomized to one of the two groups to consume one of the following test products: Nopal fruit juice or placebo juice. Questionnaire-based data collection was performed at baseline, after 2 weeks, and after 8 weeks. Blood draws were performed at the baseline visit and at the 8-week visit. Range of motion assessments of joint mobility were performed at baseline and week 8.

Study Population

People were enrolled in the study, based on the following criteria: healthy adults of either gender, age 35–75 years old, body mass index (BMI) at or below 34.9 kg/m2 with chronic joint/muscle related pain for at least the previous 6 months. People were excluded from participating if they had bariatric surgery, were diagnosed with diabetes Type I or taking medication for diabetes Type II, had a known serious chronic health condition, major surgery or trauma during the previous 3 months, serious active illness during the previous 12 months. People were also excluded if they took anti-inflammatory medications (81 mg aspirin was allowed), if they had used oral, injected or inhaled steroids during the previous 6 months (nasal sprays for allergies were allowed), or if they had used anti-inflammatory nutritional supplements, including the daily consumption of Nopal cactus fruit juice or similar products.

Forty-two people were enrolled after written informed consent (as approved by the registered Institutional Review Board Sky Lakes Medical Center Institutional Review Board FWA 2603), an IRB board that broadly serves the Klamath Falls medical research community. However, the data presented here focuses on the analysis of 40 people (20 per group) (Table 1). Two people were not included in the data analysis for the following reasons: 1) one person dropped out almost immediately after study start. Prior to her 2-week appointment, we learned that she had shingles and had not felt well enough to participate. It is unknown whether she consumed the test product before dropping out. She was in the Placebo group. Her data is not included in the tables and data graphs in this report. 2) One person completed study participation, but a critical review of her data revealed that her responses were deemed unreliable. Prior to the study she failed to report exclusionary conditions including chronic physical and mental health conditions. She was in the Nopalea group. Her data is not included in the tables and data graphs.

Table 1

Demographics of the Study Population

	Placebo	NFJ	P-value
Females	12	12
Age, averagea	56.2 ± 7.8	60.8 ± 7.5	0.16
Age range	45.8–74.4	48.8–70.7
BMI, averagea	30 ± 4.3	27.1 ± 3.7	0.09
BMI range	23.2–34.9	22.1–33.3
Males	8	8
Age, averagea	57.1 ± 11.9	54.9 ± 7.9	0.67
Age range	37–69.1	42.7–69.3
BMI, averagea	30.7 ± 3.5	28.9 ± 4.0	0.36
BMI range	25–34.8	23.4–33.5

Note: aThe group average ± standard deviation

Abbreviation: BMI, body mass index (kg/m2).

Randomization

The study participants were randomized to one of two groups, where one group consumed 3 ounces placebo daily, and the other group consumed 3 ounces NFJ daily. For pilot studies of this nature, it is important to have similar numbers of females in each group, and also similar numbers of males in each group, but not necessary to have the same number of females and males in the study. Female and male study participants were randomized separately, aiming for a similar gender distribution in the two groups. The first female was randomly assigned to a group by tossing a coin. The next female was assigned to the other group, and the group assignment alternated from here onwards. The first male was assigned to the opposite group as the first female, and the group assignment for males alternated from here onward. The study coordinator and clinic staff, as well as data analyst and auditor, were blinded until all analysis was completed and audited.

Consumable Test Products

The study involved 2 consumables: Nopalea™ Nopal fruit juice (NFJ) and a placebo juice, matched to NFJ for viscosity, color, and taste. The placebo juice had no active ingredients, was sweetened with 0.028% sucralose, thickened by guar gum and xanthan gum, colored by artificial colors, and flavored by artificial prickly pear flavor. The two juice products have similar viscosity, color, and flavor, and were bottled in identical containers with identical labels, except for different lot numbers. Instructions included taking a dose of 3 oz/day for 8 weeks. Study participants were provided with 3 oz measuring glasses.

Compliance

All bottles of juice were weighed before the beginning of the study. Study participants were instructed to return bottles containing any remaining juice at the 8-week visits, and the bottles were weighed to estimate the amount of juice consumed. The weight of 3 ounces daily for 8 weeks (56 days) was used to calculate 100% compliance. Table 2 summarizes the percent compliance

Table 2

Compliance

Product	Averagea	Range	Number of Participants
Placebo	89.3%	68.8–100%	20
Nopal fruit juice	91.8%	64.9–100%	20

Note: aThe group average ± standard deviation

Joint Range of Motion Assessment

The range of motion assessment was performed along the entire weight-bearing axis from the neck to the knees, as well as shoulder range of motion. Participants were instructed to abstain from the use of over-the-counter pain medication, such as Naproxen, for at least 18 hours, and aspirin and ibuprofen for at least 8 hours prior to the visits. The evaluation of ROM was conducted in a detailed manner using the J-Tech Tracker Freedom dual digital inclinometry (J-Tech Medical, Midvale, UT, USA), where not only a person’s major area of discomfort was evaluated but also the entire vertical weight-bearing axis of the body was studied, from the neck to the knees. In addition, shoulder ROM was also evaluated. Each ROM measurement was performed at least 2 consecutive times during each evaluation. The rationale behind this detailed assessment is that often a person’s primary complaint (eg, right hip) would lead to a compensated posture and compensated ROM of other anatomical areas as the person strived to put less pressure on a painful area, as previously described in studies for natural products.19–21

Questionnaire-Based Data Collection

At each study visit, 3 questionnaires were administered where the study participant would answer the questionnaires by use of a tablet computer in the presence of clinic staff available to answer any questions or provide clarifications. 1) A Wellness questionnaire contained questions regarding general health and wellness, designed and validated by our team to specifically capture changes in a person’s perception of health and wellness, based on the World Health Organization’s definition of “Health”: “Physical, mental, and social well-being, and not merely the absence of disease and infirmity”.32 Our research team has used the Wellness questionnaire for 10 years in clinical trials focusing on fairly healthy individuals and documenting health improvements when consuming natural products, foods, juices, alkaline waters, and botanical extracts. 2) At the time of enrollment, study participants identified their primary and secondary areas of chronic pain complaints. The pain assessments for these areas, when at rest and when physically active, were performed at baseline, 2 weeks, and 8 weeks, where the scores were measured using scales from 0–10, following previously published processes for data collection on pain in studies on natural products and dietary supplements.19–22,33 3) In addition, questions were asked as to what degree pain interfered with daily activities.20,21,33

Blood Draws

During the clinical trial, blood draws were performed at baseline and at the 8-week visit for all study participants, where 1 serum separator tube was filled, and the blood allowed to coagulate at room temperature for 30–60 minutes. The serum separator tube was centrifuged at 500 g for 15 minutes and the serum was harvested into Eppendorf tubes and frozen at −80°C.

Serum Cytokines

Serum levels of the following cytokines were tested:  IL-1beta, IL-1ra, IL-6, IL-9, IL-32, RANTES, Eotaxin, IP-10, MIP-1-beta, MCP-1, and Tumor Necrosis Factor-alpha (TNF-α), using Bio-Plex Pro™ multiplex Luminex immunoassays (Bio-Rad Laboratories, Hercules, CA, USA). Testing of these biomarkers was performed at NIS Labs using xMAP technology (Luminex, Austin, TX, USA).

C-Reactive Protein

Serum samples were shipped to Interpath Laboratories, Redmond, Oregon, USA, for testing using the high sensitivity CRP test.

Data Analysis

Statistical significance of changes from baseline to later assessments when consuming a test product was evaluated by the within-subject analysis using the two-tailed paired t-test. Statistical significance of differences between groups at baseline and at later assessments was evaluated by the between-groups analysis using the two-tailed unpaired t-test. Statistical trends are indicated if P<0.1, statistical significance is indicated if P<0.05, and a high level of significance is indicated if P<0.01.

Results

Joint Range of Motion (ROM)

Joint range of motion (ROM) was measured at baseline and after 8 weeks for the vertical weight-bearing axis from the neck to the knees and for the shoulders (Table 3). Analysis of the inclinometry data showed improvements in the NFJ group that were not seen in the placebo group. The specific improvements in joint range of motion were most robust for the cervical, thoracic, and lumbar regions, where the improvements were statistically significant between the two groups (Figure 1). For mobility in the cervical region, improvements were seen in the NFJ group for all 3 measures: lateral ROM, flexion/extension, and rotation. The difference in cervical lateral motion between the two groups reached a high level of statistical significance (P<0.006). The difference in total cervical ROM between the two groups was statistically significant (P<0.03, Figure 2A). Thoracic and lumbar ranges of motion were improved in the NFJ group, where the difference in total thoracic/lumbar range of motion reached statistical significance between the two groups (P<0.04, Figure 2B). Changes to the mobility of the hips, knees and shoulders did not reveal a significant benefit from NFJ consumption; however, it is possible that a longer study duration, or a higher dose of NFJ may have showed a difference.

Table 3

Joint Range of Motion (ROM)

Motion	Product	Baselinea	Week 8a	P-value Within Groupb	P-value Between Groupsc
Cervical Flexion/Extension	Placebo	96.1 ± 3.11	98.9 ± 2.93	NS	NS
	Nopalea	85.3 ± 3.65	92.8 ± 3.89	*
Cervical Lateral Motion	Placebo	59.9 ± 4.28	60.4 ± 4.09	NS	##
	Nopalea	52.4 ± 3.13	62.8 ± 3.37	**
Cervical Rotation	Placebo	143.4 ± 3.41	149.7 ± 4.20	(*)	NS
	Nopalea	124.2 ± 4.63	136.5 ± 4.27	**
Thoracic Rotation	Placebo	36.5 ± 2.54	37.5 ± 2.57	NS	(#)
	Nopalea	34.7 ± 3.01	41.7 ± 3.57	*
Lumbar Rotation	Placebo	27.6 ± 2.98	26.3 ± 2.56	NS	NS
	Nopalea	21.7 ± 2.65	24.9 ± 2.88	NS
Lumbar Flexion/Extension	Placebo	72.3 ± 4.01	70.7 ± 4.57	NS	NS
	Nopalea	62.9 ± 2.90	68.2 ± 3.79	NS
Sacral Hip Flexion/Extension	Placebo	51.7 ± 3.35	55.2 ± 2.76	NS	NS
	Nopalea	50.2 ± 4.88	56.2 ± 5.96	(*)
Left Shoulder Flexion/Extension	Placebo	229.3 ± 6.61	234.2 ± 4.96	NS	NS
	Nopalea	212.6 ± 4.66	219.9 ± 5.77	NS
Right Shoulder Flexion/Extension	Placebo	224.3 ± 6.55	231.2 ± 5.48	NS	NS
	Nopalea	207.4 ± 5.40	221.9 ± 6.04	*
Left Shoulder Abduction/Adduction	Placebo	175.9 ± 3.13	184.3 ± 4.15	*	NS
	Nopalea	169.4 ± 4.92	176.9 ± 5.41	*
Right Shoulder Abduction/Adduction	Placebo	167.4 ± 6.09	185.9 ± 6.23	*	NS
	Nopalea	170.4 ± 4.64	177.9 ± 5.36	(*)
Left Hip Flexion/Extension	Placebo	112.2 ± 3.16	114.3 ± 3.46	NS	NS
	Nopalea	99.6 ± 4.07	104.0 ± 4.40	NS
Right Hip Flexion/Extension	Placebo	114.6 ± 3.37	115.7 ± 3.63	NS	NS
	Nopalea	100.4 ± 3.66	105.2 ± 4.60	NS
Left Knee Flexion/Extension	Placebo	125.2 ± 2.97	128.3 ± 2.74	(*)	NS
	Nopalea	124.0 ± 2.48	123.5 ± 3.47	NS
Right Knee Flexion/Extension	PlaceboNopalea	121.9 ± 3.99121.4 ± 3.21	126.9 ± 2.64118.4 ± 5.48	NSNS	(#)

Notes: aThe average ± standard deviation of degrees of motion was recorded by dual digital inclinometry at baseline and after 8 weeks. bThis column shows within-subject statistical analysis, where NS: Not significant, (*) P<0.1, * P<0.05, and **P<0.01. cThis column shows between-group statistical analysis, where NS: Not significant, (#) P<0.1, # P<0.05; ##P<0.01.

Figure 1

Change in joint mobility.

Figure 2

Change in pain interfering with physical functioning.

Pain

The questionnaire-based data collection included several questions pertaining to pain interfering with physical functioning (Figure 2). The average change in scores for the NFJ group showed that pain interfered less with walking on a flat surface (Figure 2A) as well as sitting or lying (Figure 2B) than the average change in the placebo group. The differences between the NFJ and placebo groups were not statistically significant.

Improved Wellness Scores

Consumption of NFJ was associated with several specific, though not statistically significant, improvements in different aspects of wellness (Figure 3). Pain interfered less with daily activities for people in the NFJ group than people in the placebo group; the change was not significant (P<0.4, Figure 3A). People in the NFJ group relied less on medications than in the placebo group, reaching a statistical trend (P<0.06, Figure 3B). Breathing placed less strain on people in the NFJ group (Figure 3C).

Figure 3

Daily activities.

Change in Serum Cytokine Levels

Serum levels for 11 pro- and anti-inflammatory cytokines were tested. As expected in a fairly healthy population only 5 of the 11 cytokines were detectable in serum (Table 4). Six cytokines were below levels of detection, including Interleukin-1 receptor antagonist-a (IL-1ra), Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Interleukin-9 (IL-9), Interleukin-32, and Tumor Necrosis Factor-alpha (TNF-α). Two cytokines, namely Macrophage Inflammatory Protein-1 beta (MIP-1β) and Regulated on Activation, Normal T cell Expressed and Secreted (RANTES, CCL5), showed similar mild increases over the 8-week study in both the Nopal fruit juice group and the placebo group, with no significant differences between the Nopal fruit juice group and the placebo group. Two cytokines showed decreases in both groups, namely Monocyte Chemoattractant Protein-1 (MCP-1) and Interferon gamma-induced protein 10 (IP-10). The exception was the eosinophil chemotactic cytokine Eotaxin (CCL11), where a decrease was seen over the 8 weeks in the Nopal fruit juice group, in contrast to a mild increase in the placebo group. The difference reached statistical significance at 8 weeks (P<0.048, Figure 4).

Table 4

Serum Cytokine Levels (Pg/mL)

	Placebo			Nopal Fruit Juice			P-valuea
	N	Baseline	8 Weeks	N	Baseline	8 Weeks
MIP-1β	20	4.37 ± 0.35	5.27 ± 0.37	20	4.89 ± 0.38	6.15 ± 0.37	NS
RANTES	20	2210 ± 98	4021 ± 316	20	2079 ± 166	3640 ± 346	NS
MCP-1	20	3.16 ± 0.48	2.45 ± 0.46	20	3.23 ± 0.45	2.38 ± 0.31	NS
IP-10	20	126.2 ± 28.6	103.0 ± 14.2	20	87.67 ± 10.29	87.48 ± 14.37	NS
Eotaxin	19b	16.01 ± 1.94	16.77 ± 1.81	20	16.04 ± 1.49	15.46 ± 1.47	0.047

Notes: aP-value between the groups, using 2-tailed unpaired t-test. NS: Not significant, P>0.05. bOne study participant was removed from this analysis due to lack of compliance during the 8-week study with respect to medication that may have influenced this biomarker.

Figure 4

Serum Eotaxin levels.

Change in C-Reactive Protein

Serum levels for C-reactive protein (CRP) was tested (Table 5). The group averages were comparable for the two groups at study start. After 8 weeks, there was a mild difference in CRP levels between the placebo and NFJ groups, with an average lower level in the NFJ group, but it did not reach statistical significance. Based on our previous study on NFJ,30 we performed a sub-group analysis of the CRP levels for study participants with CRP levels below 3.0 mg/L at study start. This sub-group analysis did not show a difference between the two groups. Based on the interpretive guide for CRP levels in cardiovascular health, where people with CRP levels below 1.0 mg/L have a low risk of heart disease, sub-group analysis was performed to remove data from participants with CRP levels at or below 1.0 mg/L. In the sub-group of study participants with CRP levels above 1.0 mg/L at baseline, there was an average decrease in the NFJ group, where the difference between placebo and NFJ reached a statistical trend (P=0.06). Finally, based on the interpretive guide for the CRP levels in cardiovascular health, where people with CRP levels above 9.9 mg/L have a very high risk of heart disease, analysis of the CRP levels for study participants with CRP levels at baseline above 1.0, and those with CRP levels at baseline below 10, was performed. This showed a reduction in CRP levels in the NFJ group, in contrast to an increase in the placebo group, where the difference reached statistical significance (P<0.015).

Table 5

Serum C-Reactive Protein Levels (Mg/L)

	Placebo			Nopal Fruit Juice			P-valuea
	N	Baseline	8 Weeks	N	Baseline	8 Weeks
All study participants	20	2.84 ± 0.92	2.72 ± 0.72	20	2.41 ± 0.64	2.09 ± 0.55	0.494
CRP <3.0 mg/L at baseline	16	1.18 ± 0.18	1.57 ± 0.23	14	0.93 ± 0.18	1.04 ± 0.15	0.831
CRP >1.0 mg/L at baseline	13	4.08 ± 1.29	3.72 ± 1.00	11	3.96 ± 0.93	3.11 ± 0.90	0.060
1.0 mg/L < CRP at baseline <10.0 mg/L	12	2.95 ± 0.68	3.86 ± 1.08	10	3.26 ± 0.68	2.29 ± 0.39	0.013

Note: aP-value between the groups, using 2-tailed unpaired t-test.

Discussion

Preserving the ability to function and complete daily activities is important in healthy ageing and prolongs the time a person can maintain non-institutionalized independence, as well as reduces comorbid factors of declining health. Physical mobility plays a pivotal role for quality of life and has a preventive role in delaying the process of ageing. Declining mobility is often associated with chronic muscle and joint pain, and pharmaceutical pain management is associated with unwanted side effects. In contrast, natural food-based compounds offer methods to not only reduce pain but also to improve functionality, through reducing inflammation and supporting regenerative functions.

In the study reported here, we observed improved joint mobility in the group consuming Nopal cactus fruit juice (NFJ), when compared to the placebo group, most noticeably improved range of motion of neck, upper back, and lower back including the hips. The method we used for the measurements of joint mobility allowed evaluation of multiple areas of the body, especially the vertical weight-bearing axis from the neck to the knees, as well as the shoulders. This is different from a traditional study of osteoarthritis of the knee or hip where only one joint is evaluated, typically by simple goniometry. Our chosen methodology evaluates general mobility as a combination of joint and muscle function, as a study participant is instructed to perform complex movements, which are then recorded digitally. The results have provided objective data on improvements when consuming NFJ, compared to placebo.

The consumption of NFJ did not have a significant effect on pain scores beyond the changes seen in the placebo group, but noticeably, in the NFJ group pain interfered less with the ability to perform multiple daily activities. Furthermore, people consuming NFJ reported reduced reliance on pain medication to complete daily activities, which taken in combination supports the association of NFJ consumption with improved physical functioning and wellbeing. The results suggest that people consuming NFJ were able to be more physically active and may have increased their activity levels until they reached a similar pain level they were used to before consuming NFJ; therefore, a future follow-up study will need to track activity levels. An additional observation was that breathing problems interfered less with daily activities in the NFJ group than in the placebo group. This warrants further study, for example in a population that frequently use inhalers to complete physical activities, combined with markers associated with airway inflammation. This was further emphasized by the statistically significant change in serum levels of Eotaxin, a biomarker associated with eosinophil recruitment to inflamed tissue, including lung tissue during asthma and bronchitis,34 and related to severity during treatment.35

The serum levels of C-reactive protein (CRP) were analyzed and showed a greater reduction in the NFJ group than in the placebo group, however the difference between the two groups did not reach statistical significance. When subgroup analysis was performed, focusing on people with baseline CRP levels above 1.0 mg/L, a statistical trend was seen. When also removing data from people with very high CRP levels of 10 mg/L and higher, suggestive of a passing infection or recent injury irrelevant to the chronic pain and limited activity levels, and focusing on people with mild-to-moderate elevation of CRP at baseline (1.0–9.9 mg/L), the difference between the changes in CRP for the NFJ group and the placebo group was statistically significant. This suggests that in a population with mild to moderate inflammation, direct anti-inflammatory properties of NFJ may have helped improve the CRP levels and possibly contributed to the improved joint function and mobility.

Whereas the questionnaire-based data collection showed some interesting trends, the objective data for joint mobility and CRP levels showed definitive improvements associated with NFJ consumption, that were not seen in the placebo group. One limitation from the study reported here is that the screening criteria focused on moderate chronic pain, rather than limited mobility. Further work is needed to document modes of action involved in improved joint function and should also include tracking of physical activity for example by a fitness tracker (wrist or phone) to help evaluate whether the improvements translate to increased physical activity and intensity.

Conclusion

Consumption of Nopal fruit juice (NFJ) for 8 weeks was associated with statistically significant improvements in neck and back mobility and range of motion when compared to the placebo group, allowing participants in the NFJ group to be more physically active. In the NFJ group pain placed less limitations on daily activities, and several daily activities became easier, including walking, sitting, and lying. In the subgroup with CRP levels between 1 and 10 mg/L at baseline a reduction in CRP levels was significantly more reduced in the NFJ group than the placebo group. Taken together, the results suggest that NFJ provided support of joint mobility and physical functioning, likely via antioxidant protection and anti-inflammatory properties of NFJ.